Term
|
Definition
| inhibitors of tyrosine kinase (selective or non-selective, receptor or cystolic) |
|
|
Term
| Why are hyperactive kinases problematic? |
|
Definition
|
|
Term
| Imatinib, dasitinib, nilotinib |
|
Definition
| selective BCR/ABL TK inhibitor |
|
|
Term
|
Definition
Selective EGFR TK (at surface of many cells) inhibitor.
-Gefitinib used against non-small cell lung cancer, erlotinib used against NSCLC and pancreatic cancer |
|
|
Term
|
Definition
| chimeric monoclonal antibody against EGFR (works like gefitinib but outside cell) |
|
|
Term
| Sunitinib, lapatinib, sorafenib |
|
Definition
| Nonselective inibs (lapatinib inhibits EGFR/HER2, used for breast cancer; sorafenib inhibits VEGFR/vascular epidermal GFR and PDGF/platelet derived GFR, used for advanced renal/hepaticellular carcinoma) |
|
|
